|
|
| Research article summary (published 20 Jul 2009): |
Efficacy and safety of oxybutynin transdermal system in spinal cord injury patients with neurogenic detrusor overactivity and incontinence: an open-label, dose-titration study.
Full Abstract
OBJECTIVES: To evaluate the efficacy and safety of oxybutynin transdermal system (oxybutynin-TDS) in spinal cord injury patients with neurogenic detrusor overactivity and incontinence despite use of clean intermittent catheterization (CIC). METHODS: This multicenter, open-label, dose-titration study included patients > or = 18 years old. During an 8-week dose-titration period, oxybutynin-TDS doses were adjusted every 2 weeks, depending on symptoms. The primary efficacy end point was a change in daily number of CIC periods without leakage, from baseline to 8 weeks or last observation. Outcome parameters included 3-day voiding diary, CIC volume, and urodynamic parameters. Changes from baseline were analyzed with paired t tests. RESULTS: Of 24 study participants (mean age, 41.9 years), 18 (75.0%) completed the study. Final oxybutynin-TDS doses were 7.8, 9.1, and 11.7 mg/d for 4, 9, and 11 patients, respectively. Daily number of CIC periods without leakage increased significantly (mean change, 1.5 + or - 2.2; P = .0036) from baseline (2.4 + or - 1.8) to 8 weeks (3.9 + or - 1.9). CIC volume (P = .0029), reflex volume (P = .0466), maximal cystometric bladder capacity (P = .0009), and residual urine volume (P = .0023) all increased significantly, whereas detrusor pressure at maximal bladder capacity decreased significantly (P = .0457). The most common adverse events were application site reaction (12.5% of patients), dry mouth (8.3%), and abnormal vision (8.3%). No patient discontinued treatment because of an adverse event. CONCLUSIONS: Oxybutynin-TDS was efficacious in spinal cord injury patients with neurogenic detrusor overactivity and was well tolerated at up to 3 times the standard dose.
Author information
Author/s: Kennelly, Michael J (MJ); Lemack, Gary E (GE); Foote, Jenelle E (JE); Trop, Cynthia S (CS);
Affiliation: Carolinas Healthcare System, 1100 Blythe Boulevard, Charlotte, NC 28203, USA. mkennelly(-atsign-)carolinas.org
Journal and publication information
Publication Type: Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
Journal: Urology (Urology), published in United States. (Language: eng)
Reference: 2009-Oct; vol 74 (issue 4) : pp 741-5
Dates: Created 2009/10/05; Completed 2009/10/23;
PMID: 19628264, status: MEDLINE (last retrieval date: 10/23/2009, IMS Date: )
Sourced from the National Library of Medicine. Abstract text and other information may be subject to copyright.
External Links for this article
(including full text providers, if available):
Click Electronic Full-text Provider Links to see options for finding the electronic full text links to this article. Note there may be a subscription or fee required for access to the full text. See our FAQ for information on finding FREE full text articles.
This article may also be located in paper journal collections available in many libraries. Use the Journal and Publication Information above to find the full article.
MeSH headings (categories)
This article was linked to the MESH Headings shown below.
Related articles
These are the highest related articles currently in the database:
- [Pharmacological treatment of neurogenic detrusor hyperactivity: intradetrusor botulinum toxin A injections]
29 Apr 2007 - Intravesical atropine compared to oral oxybutynin for neurogenic detrusor overactivity: a double-blind, randomized crossover trial.
30 Dec 2006 - Re: Rufus Cartwright and Linda Cardozo. Transdermal oxybutynin: sticking to the facts. Eur urol 2007;51:907-14.
7 Apr 2007 - [Intravesical treatment of overactive bladder syndrome]
29 Sep 2006 - Can higher doses of oxybutynin improve efficacy in neurogenic bladder?
30 Jan 2004 - Transdermal oxybutynin for overactive bladder.
30 Oct 2006 - [Pharmacological treatment of neurogenic detrusor hyperactivity: intrathecal drugs]
29 Apr 2007 - Evolution of transdermal oxybutynin in the treatment of overactive bladder.
30 Dec 2007 - Transdermal drug delivery treatment for overactive bladder.
30 Aug 2006 - Botulinum toxin: a potential alternative to current treatment of neurogenic and idiopathic urinary incontinence due to detrusor overactivity.
25 Oct 2006
Related Article Map
Legend:
- FREE Full text Article.
- Abstract only.
- Title only. More help.
See a large map of 100+ related articles.